Search PubMed⌕ Search

Biomedical subjects

Y Huet

Publications and source records attributed to Y Huet.

42 records · Page 3Linked to original sources
PubMed1980

Antiarrhythmic activity of cetiedil and its analogues.

Cetiedil), originally a molecule used for treatment of some vascular diseases, exhibits several pharmacological effects. The authors studied cetiedil's stabilizing effect on the membrane and the antagonism against calcium of Cetiedil and its analogues (amino 3-thienylacetic esters). After completion of numerous pharmacological tests giving evidence of antidysrhythmic effects of the molecule and more especially in the digitalic arrhythmias and ventricular fibrillation induced by calcium (where it is more active than other products tested), the authors conclude that Cetiedil might enter in group I of Vaughan and William's classification of antiarrhythmic drugs. It is like Verapamil an inhibitor of the calcium penetration. This especially interesting antidysrhythmic profile suggests clinica research to determine the special position of Cetiedil in the treatment of heart rhythm troubles.

Adrenergic alpha-Antagonists↗
PubMed1980

[Assessment of left ventricular function in patients with aortic regurgitation using dynamic investigation (author's transl)].

To assess accurately left ventricular function (LVF) in patients with aortic regurgitation (AR pts), isometric exercise (IE) was used in association with postextrasystolic potentiation (PESP) during diagnostic heart catheterization including left cineventriculography in 16 pts with pure moderate or severe AR. The results were compared with those observed in 8 control pts (C pts). IE resulted in a significant increase in heart rate by 15 p. cent and in an increase in mean aortic pressure by 29 p. cent (p < 0.001). During IE, LV end diastolic pressure (EDP) remained unchanged in C pts and in 6 AR pts whereas this value was increased by 49 p. cent (p < 0.01) in 7 AR pts without a significant change in LV end diastolic volume. Ejection fraction (EF) was decreased in each AR pt (mean 14 p. cent; p < 0.001) and remained unchanged in C pts. A negative correlation was evidenced between the decrease in EF and the increase in LVEDP (r = 0.76). PESP resulted in a increase in EF in both C pts and AR pts (+ 25 and + 29 p. cent respectively; p < 0.001). PESP under IE resulted in a lower increase in EF than PESP under basal conditions (+ 19 and + 24 p. cent respectively) mainly due to the increase in after load provided by IE. Dynamic investigation of the LVF in AR pts is a physiological method of investigation easy to perform which may assess both LV contractile reserve and cardiac reserve. Such a method of investigation may help to select AR pts for surgery.

Adult↗
PubMedDate not supplied

Safety of preoperative enoxaparin in head and neck cancer surgery.

BACKGROUND: Thromboembolism is a risk in major head and neck cancer surgery patients predisposed to thrombosis. This study was designed to determine whether enoxaparin (a low molecular weight heparin) administered prior to surgery induces perioperative bleeding. METHODS: Forty patients scheduled for major cervicofacial cancer surgery were randomized in a double-blind study to receive either 20 mg enoxaparin or placebo, 12 hours before surgery. Blood losses were measured at the end of surgery and 6 hours later. RESULTS: Bleeding was equal in the placebo group and in the enoxaparin group, with losses of 648 +/- 106 mL and 602 +/- 106 mL (p = 0.76), respectively. Six hours after surgery, blood collected was 159.3 +/- 25.7 mL in the placebo group vs 151.4 +/- 21 mL in the enoxaparin group (p = 0.81). CONCLUSION: Preoperative administration of enoxaparin is safe in head and neck cancer surgery, but further studies are required to evaluate its efficacy in preventing thromboembolism.

Adult↗
PubMedDate not supplied

[Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study].

This open, randomised multicenter trial compares the efficacy and safety of Fragmin administered subcutaneously twice daily with standard heparin administered by continuous infusion in the treatment of deep vein thrombosis (DVT). The initial dose of Fragmin is 100 U anti-Xa/kg/12 h and the further doses are adjusted according to the anti-Xa activity between 0.5 and 0.8 U/ml, 3 hours after the morning injection. The initial dose of standard heparin is 240 UI/kg/12 h. The dose adjustments are based on the daily results of APTT (1.5 - 3 times the control). Treatments efficacy are appreciated when comparing the venography performed before and after 10 days of treatment. The safety is evaluated on clinical parameters and iterative biological tests. Sixty-six patients have been included in this study. Efficacy of the two treatments is equivalent with a phlebographic improvement in respectively 79.3 p. 100 (Heparin Group) and 71.0 p. 100 (Fragmin Group) of the cases and an aggravation in 3.4 p. 100 and 6.4 p. 100 (NS) respectively. The frequency of dosage adjustments is lower and the stability of biological tests is better in the Fragmin group. In conclusion, the administration of Fragmin twice daily by subcutaneous route seems to be equivalent at least to standard heparin continuous infusion in the treatment of recent DVT. The better convenience and safety of Fragmin have to be verified on a larger panel of patients.

Adult↗